Biopharmaceutical Network Expansion with New Strategic Collaborations and Policy Connections
Five new co-actors, including key pharmaceutical companies (Amgen, GlaxoSmithKline, Kiniksa Pharmaceuticals, Pfizer) and a prominent research institution (Calibr-Skaggs), have joined an existing network. This expansion, coupled with the prior inclusion of the US Senate and a biotech review involving Sangamo and IDEAYA Biosciences, indicates a growing web of strategic collaborations within the biopharmaceutical sector, likely driven by both research advancements and evolving policy considerations.
dormant
auto detected
Confidence: 85%Created: Oct 04, 2026 01:06
Last activity: Oct 04, 2026 01:06
Sentinel
tier: low
Participants (11)
Kiniksa Pharmaceuticals International 3 evAlabama Gas Corporation 3 evCalibr-Skaggs Institute For Innovative Medicines 3 evGlaxosmithkline 3 evUnited States Senate 3 evDow Agrosciences 3 evUniversity Of Greater Manchester 3 evPfizer 3 evCancer Research United Kingdom 3 evAmgen 3 evWerner Herzog 3 ev
Recent events (1)
Sangamo Therapeutics (NASDAQ:SGMO) & IDEAYA Biosciences (NASDAQ:IDYA) Head to Head Review
Event Timeline
Subject
Object
Co-mention